These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 16168052)

  • 21. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells.
    Usui-Ouchi A; Ouchi Y; Ebihara N
    Int Immunopharmacol; 2017 Nov; 52():70-76. PubMed ID: 28866026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new insight into the treatment of diabetes by means of pan PPAR agonists.
    Chandra A; Kaur P; Sahu SK; Mittal A
    Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Staels B; Fruchart JC
    Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
    Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
    Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPAR Agonists and Metabolic Syndrome: An Established Role?
    Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPAR agonists for the treatment of neuroinflammatory diseases.
    Titus C; Hoque MT; Bendayan R
    Trends Pharmacol Sci; 2024 Jan; 45(1):9-23. PubMed ID: 38065777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
    Pershadsingh HA
    Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the peroxisome proliferator-activated receptors (PPAR)-α, β/δ and γ triad in regulation of reactive oxygen species signaling in brain.
    Aleshin S; Reiser G
    Biol Chem; 2013 Dec; 394(12):1553-70. PubMed ID: 24021597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery Approaches for Novel Dyslipidemia Drugs.
    Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
    Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 40. Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk.
    Millar JS
    Curr Opin Lipidol; 2013 Jun; 24(3):233-8. PubMed ID: 23594710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.